Nortriptyline
Brand names: Allegron
Nortriptyline is a tricyclic antidepressant used in the treatment of depression and also for neuropathic pain.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It inhibits the reuptake of noradrenaline and, to a lesser extent, serotonin at central synapses, increasing their availability; it is the active metabolite of amitriptyline.
Prescribing in practice
- Tricyclic antidepressants are dangerous in overdose, causing cardiac arrhythmias and seizures, so caution is needed in patients at risk of suicide and quantities supplied should be considered carefully.
- It has anticholinergic and cardiac effects and should be used with caution in the elderly and in those with cardiovascular disease, urinary retention, glaucoma or epilepsy.
- Avoid concomitant use with MAO inhibitors and use serotonergic combinations cautiously because of the risk of serotonin syndrome.
Monitoring
Monitor mood and suicidal ideation, cardiovascular status and anticholinergic side effects, with ECG considered where cardiac risk factors are present.
Counselling the patient
- This medicine may cause drowsiness, dry mouth or constipation, particularly when starting.
- It can take a few weeks to feel the full benefit, so keep taking it as prescribed.
- Do not stop abruptly; your prescriber will advise on reducing the dose gradually.
Evidence & guidelines
Nortriptyline is a long-established tricyclic antidepressant, and the dangers of tricyclics in overdose are well documented and reflected in NICE depression guidance.
Reference: NICE NG59 (Neuropathic Pain); Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Acute Behavioural Disturbance / Rapid Tranquillisation · RCEM 2022; RCPsych 2022; NICE NG10
- Self-Harm Presentation · NICE NG225 (2022)
- Capacity Assessment (Mental Capacity Act) · MCA 2005; Code of Practice
- Acute Psychosis Management · NICE CG178 2014
- Depression Management · NICE CG90 2022
- Lithium Therapy Monitoring · NICE CG185